Robert E. Donohue, MD, presented “Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Con Argument” during the 28th Annual Perspectives in Urology: Point Counterpoint on November 16, 2019 in Scottsdale, Arizona.
How to cite: Donohue, Robert E. “Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Con Argument” November 16, 2019. Accessed Nov 2024. https://prostate-cancer-screening-and-early-detection-should-we-follow-the-nccn-guidelines-con-argument/
Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Con Argument – Summary:
Robert E. Donohue, MD, argues against urologists adhering to the National Comprehensive Cancer Network (NCCN) Prostate Cancer Screening and Early Detection Guidelines. He proposes his own definitive answers to controversial questions relating to the use of digital rectal exams and PSA tests in baseline evaluation, indications for biopsy and biopsy technique, the age for initiation and discontinuation of testing, the frequency of testing, screening in high-risk populations, and which biomarkers to use.
The “pro” rebuttal to this presentation is “Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Pro Argument” by A. Karim Kader, MD, PhD.
About Perspectives in Urology: Point Counterpoint
Perspectives in Urology: Point Counterpoint (PCP) is an annual, multi-day, CME-accredited conference devoted to discussing and debating the latest topics in men’s health and general urology, as well as management of bladder, renal, and both localized and advanced prostate cancer. More than didactic lectures, the conference’s format includes debates, point-counterpoint discussion panels, and unique case-based presentations. Dr. Donohue presented this lecture during the 28th PCP in 2019. Please visit this page in order to register for future PCP meetings.
